CHONGQING LUMMY PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.69 CNY | -0.37% |
|
-0.74% | -27.69% |
| Sales 2022 | 885M 122M | Sales 2023 | 896M 124M | Capitalization | 3.93B 542M |
|---|---|---|---|---|---|
| Net income 2022 | -68M -9.38M | Net income 2023 | -8M -1.1M | EV / Sales 2022 | 4 x |
| Net cash position 2022 | 481M 66.38M | Net cash position 2023 | 566M 78.06M | EV / Sales 2023 | 3.75 x |
| P/E ratio 2022 |
-58.5
x | P/E ratio 2023 |
-438
x | Employees | 800 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 32.5% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.37% | ||
| 1 week | -0.74% | ||
| Current month | -12.66% | ||
| 1 month | -12.09% | ||
| 3 months | -17.23% | ||
| 6 months | -28.84% | ||
| Current year | -27.69% |
1 week
2.58
2.75
1 month
2.453.17
Current year
2.033.85
1 year
2.034.75
3 years
2.0312.14
5 years
2.0312.14
10 years
2.0322.08
| Managers | Title | Age | Since |
|---|---|---|---|
Rong Zhao Qiu
CEO | Chief Executive Officer | 30 | 20-06-11 |
Wen Lai
DFI | Director of Finance/CFO | 50 | 02-12-31 |
Yuan Yuan
CHM | Chairman | 42 | 11-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xue Feng Leng
BRD | Director/Board Member | 52 | - |
Zhang Bi Li
BRD | Director/Board Member | 52 | 20-07-12 |
Hui Chuan Xu
CTO | Chief Tech/Sci/R&D Officer | 46 | 06-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 2.69 | -0.37% | 16,618,000 |
| 24-04-23 | 2.7 | +1.50% | 13,208,100 |
| 24-04-22 | 2.66 | +0.76% | 10,131,450 |
| 24-04-19 | 2.64 | -0.75% | 8,612,440 |
| 24-04-18 | 2.66 | -1.85% | 12,407,280 |
End-of-day quote Shenzhen S.E., April 23, 2024
More quotes
Chongqing Lummy Pharmaceutical Co.,Ltd is a China-based company principally engaged in the research, development, manufacture and sale of medicines. The Companyâs medicines consist of anti-infection medicines, special medicines, infusion, Chinese patent drugs and herbal decoction pieces. The Company's main products include carbon nanoparticles suspension injection, omeprazole enteric capsules, mycobacterium phlei F.U.36 injection, levofloxacin hydrochloride and tranexamic acid and sodium chloride injection, among others. The Company distributes its products in domestic market.
Sector
Pharmaceuticals
Calendar
2024-09-01
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -27.69% | 392M | |
| +25.61% | 660B | |
| +25.87% | 562B | |
| -5.24% | 358B | |
| +16.49% | 322B | |
| +8.28% | 297B | |
| +7.09% | 219B | |
| -9.12% | 196B | |
| +5.01% | 199B | |
| -8.75% | 149B |
- Stock Market
- Equities
- 300006 Stock
